Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holten-Andersen, M. N.
Right arrow Articles by Brünner, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holten-Andersen, M. N.
Right arrow Articles by Brünner, N.
Clinical Cancer Research Vol. 6, 4292-4299, November 2000
© 2000 American Association for Cancer Research


Regular Articles

High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer1

Mads Nikolaj Holten-Andersen, Ross W. Stephens, Hans Jørgen Nielsen, Gillian Murphy, Ib Jarle Christensen, William Stetler-Stevenson and Nils Brünner2

Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen, Denmark [M. N. H-A., R. W. S., I. J. C., N. B.]; Department of Surgical Gastroenterology, Hvidovre Hospital, 2650 Hvidovre, DK-2650 Denmark [H. J. N.]; School of Biological Sciences, University of East Anglia, Norwich, NR4 7T3 United Kingdom [G. M.]; and Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892-1500 [W. S-S.]

ABSTRACT

The objective of the present study was to measure preoperative plasma tissue inhibitor of metalloproteinase (TIMP)-1 levels in colorectal cancer patients and relate these values to clinical and biochemical patient characteristics. TIMP-1 levels were determined by ELISA in EDTA plasma samples collected preoperatively from 588 colorectal cancer patients. Plasma TIMP-1 levels were distributed with a median value of 141.1 µg/liter (range, 53.7–788.7 µg/liter). Whereas no significant differences were found in the median plasma TIMP-1 levels among patients with Dukes’ stage A, B, and C disease, patients with Dukes’ stage D disease had significantly higher plasma TIMP-1 levels (P < 0.0001); however, high plasma TIMP-1 levels were not restricted to advanced disease. A relatively weak correlation between plasma TIMP-1 level and age was found (r = 0.35; P < 0.0001). There was no significant difference in TIMP-1 levels between males and females (P = 0.97). Univariate analysis demonstrated an increasing risk of mortality with increasing TIMP-1 levels [scored as the loge(TIMP-1); hazard ratio = 3.3; 95% confidence interval, 2.6–4.2; P < 0.0001]. Including covariates (Dukes’ stage, primary tumor location, gender, age, plasminogen activator inhibitor type 1, and soluble urokinase plasminogen activator receptor) in a multivariate analysis, TIMP-1 was retained in the final model (hazard ratio = 2.5; 95% confidence interval, 1.7–3.7; P < 0.0001). This study showed a highly significant association between preoperative plasma TIMP-1 levels and survival in colorectal cancer patients, with higher plasma TIMP-1 levels being associated with poor outcome. Independent of clinical parameters including Dukes’ stage, plasma TIMP-1 levels were found to strongly predict prognosis of colorectal cancer patients. Additional studies are needed to validate the clinical usefulness of plasma TIMP-1 measurements.




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
S. O. Wurtz, S. Moller, H. Mouridsen, P. B. Hertel, E. Friis, and N. Brunner
Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer: A Prospective Study
Mol. Cell. Proteomics, February 1, 2008; 7(2): 424 - 430.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
Y.-S. Kim, S. Y. Hwang, H.-Y. Kang, H. Sohn, S. Oh, J.-Y. Kim, J. S. Yoo, Y. H. Kim, C.-H. Kim, J.-H. Jeon, et al.
Functional Proteomics Study Reveals That N-Acetylglucosaminyltransferase V Reinforces the Invasive/Metastatic Potential of Colon Cancer through Aberrant Glycosylation on Tissue Inhibitor of Metalloproteinase-
Mol. Cell. Proteomics, January 1, 2008; 7(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. Varghese, M. Burness, H. Xu, T. Beresnev, J. Pingpank, and H. R. Alexander
Site-Specific Gene Expression Profiles and Novel Molecular Prognostic Factors in Patients with Lower Gastrointestinal Adenocarcinoma Diffusely Metastatic to Liver or Peritoneum
Ann. Surg. Oncol., December 1, 2007; 14(12): 3460 - 3471.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. M. Sorensen, P. Bystrom, I. J. Christensen, A. Berglund, H. J. Nielsen, N. Brunner, and B. Glimelius
TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid
Clin. Cancer Res., July 15, 2007; 13(14): 4117 - 4122.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
M. Thaysen-Andersen, I. B. Thogersen, H. J. Nielsen, U. Lademann, N. Brunner, J. J. Enghild, and P. Hojrup
Rapid and Individual-specific Glycoprofiling of the Low Abundance N-Glycosylated Protein Tissue Inhibitor of Metalloproteinases-1
Mol. Cell. Proteomics, April 1, 2007; 6(4): 638 - 647.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
I. V. Sorensen, C. Fenger, H. Winther, N. T. Foged, U. Lademann, N. Brunner, and P. A. Usher
Characterization of Anti-TIMP-1 Monoclonal Antibodies for Immunohistochemical Localization in Formalin-fixed, Paraffin-embedded Tissue
J. Histochem. Cytochem., October 1, 2006; 54(10): 1075 - 1086.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen
Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein
Clin. Cancer Res., May 1, 2005; 11(9): 3257 - 3264.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A.-S. Schrohl, M. N. Holten-Andersen, H. A. Peters, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, N. Brunner, and J. A. Foekens
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer
Clin. Cancer Res., April 1, 2004; 10(7): 2289 - 2298.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Bloomston, E. E. Zervos, and A. S. Rosemurgy II
Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials
Ann. Surg. Oncol., August 1, 2002; 9(7): 668 - 674.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner, and T. Piironen
Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay
Clin. Chem., August 1, 2002; 48(8): 1305 - 1313.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Utsunomiya, Y. Hara, A. Kataoka, M. Morita, H. Arakawa, M. Mori, and S. Nishimura
Cystatin-like Metastasis-associated Protein mRNA Expression in Human Colorectal Cancer Is Associated with Both Liver Metastasis and Patient Survival
Clin. Cancer Res., August 1, 2002; 8(8): 2591 - 2594.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, R. W. Stephens, V. Jensen, O. H. Nielsen, S. Sorensen, J. Overgaard, H. Lilja, A. Harris, et al.
Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer
Clin. Cancer Res., January 1, 2002; 8(1): 156 - 164.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Yan and M. A. Moses
A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma
Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.